Sinoway Industrial Co., Ltd.

Otsuka Mikeluna (Carteolol / Latanoprost) Compound Eye Drops Approved By Japan For The Treatment Otsuka Mikeluna (Carteolol / Latanoprost) Compound Eye Drops Approved By Japan For The Treatment

Japanese drugmaker Otsuka recently announced that Mikeluna's ophthalmic pharmaceutical eye drops, approved by Japanese regulators, are being approved for the treatment of glaucoma and ocular hypertension. The drug R & D production by Otsuka, Otsuka and Japan's joint promotion of thousands of pharmaceutical.

Mikeluna consists of the non-selective beta blocker cartelol hydrochloride and the prostaglandin analog latanoprost. Carteolol hydrochloride is a non-selective β-adrenergic receptor blockers, both β1 and β2 receptors have a block effect on ocular hypertension and ocular hypertension in patients with intraocular pressure, glaucoma patients 1 hour after instillation began to reduce intraocular pressure, 4 hours maximum intraocular pressure, ocular hypotensive effect sustainable 8-24 hours; the mechanism of its antihypertensive effect is to reduce the formation of aqueous humor, the aqueous through the uveal scleral outflow, Room water flow and sclera superior venous pressure has no effect. The main metabolite of carteolol hydrochloride is 9-hydroxy-carteolol, which is an ocular beta-blocker and also has an ocular hypotensive effect.

Latanoprost, an analog of prostaglandin F2a, is a selective FP receptor agonist, an inactivated substance that rapidly penetrates into the cornea and is hydrolysable to activity in the cornea and plasma Of free acid, can reduce the intraocular pressure by increasing the outflow of aqueous humor. Patients began 3-4 hours after instillation began to reduce intraocular pressure, 8-12 hours to achieve maximum effect, IOP reduction effect for at least 24 hours; its main mechanism of action to increase the aqueous humor of the scleral outflow, with good IOP reduction effect. Mainly used to reduce open-angle glaucoma and ocular hypertension in patients with elevated intraocular pressure.

In general, glaucoma is treated as a single agent when initially treated, and if intraocular pressure is not adequately controlled, additional medication is prescribed for treatment. However, the need to wait for another period of time after applying one eye drop will result in a decrease in adherence, which may reduce the efficacy of the treatment. The two drugs together, is expected to significantly improve the treatment compliance.
Related Blog
  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China